Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
This article was originally published in The Tan Sheet
Executive Summary
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
You may also be interested in...
Kos Statin/Niacin Fixed Dose Combo To Be Supported By NHLBI-Funded Trial
The National Heart, Lung & Blood Institute will provide more than $20 mil. in funding for a clinical study comparing a simvastatin/niacin combination therapy to simvastatin alone for prevention of cardiovascular events
Kos Statin/Niacin Fixed Dose Combo To Be Supported By NHLBI-Funded Trial
The National Heart, Lung & Blood Institute will provide more than $20 mil. in funding for a clinical study comparing a simvastatin/niacin combination therapy to simvastatin alone for prevention of cardiovascular events
Kos Statin/Niacin Fixed Dose Combo To Be Supported By NHLBI-Funded Trial
The National Heart, Lung & Blood Institute will provide more than $20 mil. in funding for a clinical study comparing a simvastatin/niacin combination therapy to simvastatin alone for prevention of cardiovascular events